Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: A French multicenter prospective study

Archives of Dermatology

Volumn 148, Issue 4, 2012, Pages 479-484

  Francès, Camille ^a   Cosnes, Anne ^b   Duhaut, Pierre ^c   Zahr, Noël ^a   Soutou, Boutros ^a   Ingen Housz Oro, Saskia ^b   Bessis, Didier ^d   Chevrant Breton, Jacqueline ^e   Cordel, Nadège ^f   Lipsker, Dan ^g   Costedoat Chalumeau, Nathalie ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f Gynecology and Obstetric Unit   (Guadeloupe)

^g UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE SULFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILBLAIN LUPUS; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS TUMIDUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANNICULITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SKIN LUPUS ERYTHEMATOSUS; SUBACUTE SKIN LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; CHILBLAINS; CHILD; FEMALE; FRANCE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANNICULITIS, LUPUS ERYTHEMATOSUS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859992864     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2558     Document Type: Article

References (20)

1. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365-381.
2. Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus. 2010;19(9):1125-1136.
3. Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol. 2000;27(7):1656-1660. (Pubitemid 30462807)
4. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-responserelationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6): 1460-1469. (Pubitemid 34620191)
5. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(10): 3284-3290. (Pubitemid 44622099)
6. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010;19(9):1050-1070.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277. (Pubitemid 13221242)
8. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):821-824. (Pubitemid 46846706)
9. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211-2221.
10. Costedoat-Chalumeau N, Leroux G, Piette J-C, Amoura Z. Antimalarials and systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon JP, Koike T, eds. Systemic Lupus Erythematosus. 5th ed. New York, NY: Elsevier Science Inc; 2010: 1061-1081.
11. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775-784.
12. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.
13. Rigaudière F, Ingster-Moati I, Hache JC, et al. Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment [in French]. J Fr Ophtalmol. 2004;27(2):191-199. (Pubitemid 38391630)
14. Leroux G, Costedoat-Chalumeau N, Hulot JS, et al. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis. 2007; 66(11):1547-1548. (Pubitemid 350032673)
15. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J AmAcad Dermatol. 2000; 42(6):983-987. (Pubitemid 30368665)
16. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of anti-malarial therapy in cutaneous lupus. J Rheumatol. 1998;25(9):1716-1719. (Pubitemid 28439264)
17. Boeckler P, Milea M, Meyer A, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men: a focus on combined C2/C4 deficiency. Br J Dermatol. 2005;152(2):265-270. (Pubitemid 40343596)
18. Koskenmies S, Järvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus. 2008;17(4):337-347. (Pubitemid 351655803)
19. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009;145(3): 255-260.
20. Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus [published correction appears in Br J Dermatol. 2010;163(4):898]. Br J Dermatol. 2010;163(1):83-92.